Zydus Lifesciences Limited
ZYDUSLIFE
Rang in Aktien
#1749
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Aktienkurs
$12.30
Marktkapitalisierung
$12.27B
Veränderung (1 Tag)
0.06%
Veränderung (1 Jahr)
8.33%
Land
IN
Handel Zydus Lifesciences Limited (ZYDUSLIFE)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Zydus Lifesciences Limited (ZYDUSLIFE)
Anzahl der ausstehenden Aktien zum June 2026: 1.01B
Laut den neuesten Finanzberichten und dem Aktienkurs von Zydus Lifesciences Limited beträgt die aktuelle Anzahl der ausstehenden Aktien 1.01B. Am Ende von March 2024 hatte das Unternehmen 1.01B ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Zydus Lifesciences Limited (ZYDUSLIFE) von 2004 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 1.01B | -0.12% |
| 2025 | 1.01B | -0.55% |
| 2024 | 1.01B | -0.37% |
| 2023 | 1.02B | -0.79% |
| 2022 | 1.02B | 0.00% |
| 2021 | 1.02B | 0.00% |
| 2020 | 1.02B | 0.00% |
| 2019 | 1.02B | 0.00% |
| 2018 | 1.02B | 0.00% |
| 2017 | 1.02B | 0.00% |
| 2016 | 1.02B | 0.00% |
| 2015 | 1.02B | 0.00% |
| 2014 | 1.02B | 0.00% |
| 2013 | 1.02B | 0.00% |
| 2012 | 1.02B | 0.00% |
| 2011 | 1.02B | 0.00% |
| 2010 | 1.02B | 0.00% |
| 2009 | 1.02B | 8.67% |
| 2008 | 942.10M | 0.00% |
| 2007 | 942.10M | 0.00% |
| 2006 | 942.10M | 100.00% |
| 2005 | 471.05M | 0.00% |
| 2004 | 471.05M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 138.71% |
IN
|
